Post by Deleted on Jan 9, 2017 20:11:52 GMT
Big day for Oncology players after Ariad sale, Merck/Incyte deal
Jan. 9, 2017 2:51 PM ET|By: Stephen Alpher, SA News Editor
•NewLink Genetics (reported earlier) , Exelixis (EXEL +13.9%), Clovis Oncology (CLVS +8.5%), Loxo Oncology (LOXO +7.1%), and Array BioPharma (ARRY +4.6%) are among those with their tails in the air after Takeda takes out Ariad for a 75% premium to Friday's close.
•Also of news in the sector is Incyte's expanded cancer collaboration with Merck.
C L
Jan. 9, 2017 2:51 PM ET|By: Stephen Alpher, SA News Editor
•NewLink Genetics (reported earlier) , Exelixis (EXEL +13.9%), Clovis Oncology (CLVS +8.5%), Loxo Oncology (LOXO +7.1%), and Array BioPharma (ARRY +4.6%) are among those with their tails in the air after Takeda takes out Ariad for a 75% premium to Friday's close.
•Also of news in the sector is Incyte's expanded cancer collaboration with Merck.
C L